S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Inhibikase Therapeutics (IKT) Competitors

$2.04
-0.06 (-2.86%)
(As of 04/19/2024 ET)

IKT vs. COEP, SQZ, EVAX, SNTI, GENE, ONVO, BCDA, SRNE, PMCB, and CELZ

Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Coeptis Therapeutics (COEP), SQZ Biotechnologies (SQZ), Evaxion Biotech A/S (EVAX), Senti Biosciences (SNTI), Genetic Technologies (GENE), Organovo (ONVO), BioCardia (BCDA), Sorrento Therapeutics (SRNE), PharmaCyte Biotech (PMCB), and Creative Medical Technology (CELZ). These companies are all part of the "biological products, except diagnostic" industry.

Inhibikase Therapeutics vs.

Inhibikase Therapeutics (NYSE:IKT) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 20.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Inhibikase Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 1,223.53%. Coeptis Therapeutics has a consensus price target of $3.00, indicating a potential upside of 806.34%. Given Inhibikase Therapeutics' higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Coeptis Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Coeptis Therapeutics has a net margin of 0.00% compared to Inhibikase Therapeutics' net margin of -5,886.15%. Inhibikase Therapeutics' return on equity of -107.54% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibikase Therapeutics-5,886.15% -107.54% -91.82%
Coeptis Therapeutics N/A -794.75%-322.86%

Inhibikase Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.89, indicating that its share price is 189% less volatile than the S&P 500.

Inhibikase Therapeutics and Coeptis Therapeutics both received 5 outperform votes by MarketBeat users. However, 100.00% of users gave Coeptis Therapeutics an outperform vote while only 83.33% of users gave Inhibikase Therapeutics an outperform vote.

CompanyUnderperformOutperform
Inhibikase TherapeuticsOutperform Votes
5
83.33%
Underperform Votes
1
16.67%
Coeptis TherapeuticsOutperform Votes
5
100.00%
Underperform Votes
No Votes

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for Inhibikase Therapeutics and 1 mentions for Coeptis Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inhibikase Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Coeptis Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inhibikase Therapeutics has higher revenue and earnings than Coeptis Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase Therapeutics$260K50.84-$19.03M-$3.56-0.57
Coeptis Therapeutics$80K149.32-$21.27M-$0.84-0.39

Summary

Inhibikase Therapeutics and Coeptis Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKT vs. The Competition

MetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$13.22M$2.58B$4.83B$17.14B
Dividend YieldN/A2.31%2.93%3.62%
P/E Ratio-0.5724.64211.8623.05
Price / Sales50.84266.292,453.999.70
Price / CashN/A145.7646.5617.06
Price / Book1.153.744.544.85
Net Income-$19.03M-$43.47M$103.98M$970.56M
7 Day Performance-6.85%-9.01%-4.48%-1.76%
1 Month Performance-0.49%-12.62%-6.64%-3.82%
1 Year Performance-44.26%2.74%7.73%100.03%

Inhibikase Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COEP
Coeptis Therapeutics
1.2132 of 5 stars
$0.39
+11.5%
$3.50
+799.7%
-76.5%$14.04M$80,000.00-0.464News Coverage
SQZ
SQZ Biotechnologies
0 of 5 stars
$0.05
flat
N/A-99.3%$12.83M$18.16M-0.0253
EVAX
Evaxion Biotech A/S
2.1182 of 5 stars
$3.96
-3.2%
$11.00
+177.8%
-68.1%$16.04M$70,000.00-0.5963Gap Down
SNTI
Senti Biosciences
2.1379 of 5 stars
$0.35
-5.4%
$6.00
+1,611.8%
-67.6%$16.04M$2.56M-0.2248Positive News
GENE
Genetic Technologies
0 of 5 stars
$2.88
+2.1%
N/A-58.9%$10.85M$8.49M0.0060News Coverage
Gap Up
ONVO
Organovo
0.453 of 5 stars
$1.05
+1.0%
N/A-47.4%$10.52M$370,000.00-0.4818Analyst Report
News Coverage
BCDA
BioCardia
2.784 of 5 stars
$0.39
+2.6%
$4.00
+918.3%
-81.7%$10.50M$480,000.00-0.7116
SRNE
Sorrento Therapeutics
0 of 5 stars
$0.02
+100.0%
N/A-94.3%$9.44M$60.32M0.00799Analyst Report
News Coverage
Gap Down
PMCB
PharmaCyte Biotech
0 of 5 stars
$2.30
-3.8%
N/A-28.6%$19.44MN/A-1.922Gap Down
CELZ
Creative Medical Technology
0 of 5 stars
$5.64
+2.0%
N/A-27.1%$7.67M$10,000.00-1.524News Coverage
Positive News

Related Companies and Tools

This page (NYSE:IKT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners